Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hemolytic Anemia Clear all
Terminated Phase 1 Interventional Results available

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

NCT02231710
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies, Metabolic Disorders
Interventions
BPX-501 and Rimiducid
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
4 Months to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

sPLA2 in EBC During Acute Chest Syndrome

NCT03250585
View directory record Official record
Conditions
Sickle Cell Disease, Acute Chest Syndrome
Interventions
Exhaled Breath Condensate (EBC), Plasma Sample
Diagnostic Test
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
7 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

SALT: Alternative Donor Bone Marrow and Cord Blood Transplantation for High Risk Sickle Cell Disease

NCT00257543
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alternative donor bone marrow and cord blood
Procedure
Lead sponsor
Emory University
Other
Eligibility
Up to 16 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease

NCT01959958
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Questionnaire/Interview
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

NCT05348915
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Decitabine for High-Risk Sickle Cell Disease

NCT01375608
View directory record Official record
Conditions
Neutropenia, Sickle Cell Disease
Interventions
Decitabine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Oral Nifedipine to Treat Iron Overload

NCT00712738
View directory record Official record
Conditions
Thalassemia, Iron Overload, Hemochromatosis
Interventions
Nifedipine, Phlebotomy, Urinalysis, Echocardiogram, Electrocardiogram
Drug · Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Results available

Efficacy and Safety of RBCs Derived From Mirasol-treated Whole Blood in Patients Requiring Chronic Transfusion (PRAISE)

NCT03329404
View directory record Official record
Conditions
Transfusion Dependent Thalassemia
Interventions
Mirasol Red Blood Cells (MIR RBCs), Reference Red Blood Cells (REF RBCs)
Device
Lead sponsor
Terumo BCTbio
Industry
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Oakland, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

NCT03075878
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
ALXN1830
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)

NCT07656415
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Mitapivat Matched Placebo, Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan • Flowood, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)

NCT01737814
View directory record Official record
Conditions
Vaso-occlusive Crisis, Sickle Cell Disease
Interventions
Saline, MST-188
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
4 Years to 65 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
50
States / cities
Mobile, Alabama • Phoenix, Arizona • Oakland, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1 Interventional

A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

NCT04055818
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Nicotinamide
Drug
Lead sponsor
EpiDestiny, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 1Phase 2 Interventional

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

NCT00738413
View directory record Official record
Conditions
Thalassemia
Interventions
Deferoxamine, Deferasirox
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2010 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT04661033
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
Isatuximab SAR650984
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Improving Sickle Cell Disease (SCD) Care Using Web-based Guidelines

NCT03037021
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
15 Years to 45 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

NCT06412497
View directory record Official record
Conditions
Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
Interventions
Rituximab, Rabbit ATG, Cyclophosphamide, Fludarabine, Total Body Irradiation, Cell Infusion, Post-Transplant G-CSF, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

NCT01476696
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Prasugrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Oakland, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

NCT02417298
View directory record Official record
Conditions
Pain, Sickle Cell Disorder
Interventions
Normal saline, Ketamine
Drug
Lead sponsor
Billy Sin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Not applicable Interventional

Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease

NCT03353584
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Virtual Reality Therapy
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 25 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

NCT00502788
View directory record Official record
Conditions
Hepatitis C, Thalassemia
Interventions
Peginterferon Alfa-2a and Ribavirin, Ribavirin
Drug
Lead sponsor
Carelon Research
Other
Eligibility
18 Years to 44 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Oakland, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Development and Adaptation of I-STRONG for SCD

NCT06110754
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
I-STRONG for SCD
Behavioral
Lead sponsor
Emory University
Other
Eligibility
12 Years to 18 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Atlanta, Georgia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional

THE IMPROVE TRIAL: Improving Pain Management and Outcomes With Various Strategies of Patient-Controlled Analgesia (PCA)

NCT00999245
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
High Demand / Low Infusion, PCA Dosing Plan
Other
Lead sponsor
Carelon Research
Other
Eligibility
10 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
28
States / cities
Oakland, California • New Haven, Connecticut • Wilmington, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects

NCT02567695
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

NCT03225287
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
Zilucoplan (RA101495)
Drug
Lead sponsor
Ra Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 17, 2026, 5:15 AM EDT